The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: 0.00 (0.00%)
Spread: 0.40 (0.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 120.40
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Syncona confident after Q1 market volatility

Tue, 16th Aug 2022 10:06

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.33bn at the end of its first quarter on Tuesday, or 197.9p per share, up from £1.31bn and 194.4p per share at the end of March.

The FTSE 250 company said that made for a net asset value return of 1.8% in the three months ended 30 June, driven by the positive impact of foreign exchange across the portfolio and capital pool.

Its life science portfolio was valued at £561.8m, up from £524.9m, with a return of -0.2% in the quarter.

The share prices of Syncona's listed holdings were still being negatively impacted by market volatility, although the board said it remained "confident" in the fundamentals of its companies.

It added that the portfolio remained funded to deliver on upcoming clinical milestones in the 2023 financial year, with £38m deployed in the period and a capital base of £768.7m as at 30 June, down from £784.9m at the end of March.

The company said that capital base provided it with a strategic advantage, as it looked to fund "exciting" new opportunities while supporting its current portfolio.

"We are pleased with the continued progress across the Syncona portfolio during the quarter, with our companies delivering on a number of operational and clinical milestones," said Martin Murphy, chair and chief executive officer at Syncona Investment Management.

"Our strategic capital base remains a key competitive advantage, enabling us to continue to fund our companies through the current market conditions, with £38m of capital deployed in the quarter, and strongly positioning us to take advantage of exciting opportunities to found new Syncona companies."

Murphy said Syncona was founded with a long-term vision and approach to leverage its experience in managing life science companies through all market cycles.

"We are confident that we can navigate the current environment to deliver strong risk-adjusted returns for our shareholders and fulfil our purpose to extend and enhance human life."

At 0940 BST, shares in Syncona were down 0.2% at 199.2p.

Reporting by Josh White at Sharecast.com.

More News
22 Dec 2022 08:04

Syncona investee Autolus sells more American shares

(Sharecast News) - Life science-focussed healthcare company Syncona said on Thursday that its portfolio company Autolus Therapeutics had announced that the underwriters of its public offering of American depositary shares (ADSs), which closed on 13 December, had partially exercised their option to purchase an additional 6,927,102 ADSs.

Read more
9 Dec 2022 10:36

Syncona portfolio firm hits 70% remission rate goal in leukaemia trial

(Alliance News) - Syncona Ltd on Friday said portfolio company Autolus Therapeutics PLC achieved the primary endpoint in the clinical trial of its treatment for acute lymphoblastic leukaemia.

Read more
9 Dec 2022 07:21

Syncona's Autolus leukemia treatment meets trial endpoint

(Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.

Read more
6 Dec 2022 12:00

Syncona investee Achilles continues to progress cancer trials

(Alliance News) - Syncona Ltd on Tuesday noted the continued positive progress in lung cancer trials by its portfolio company.

Read more
1 Dec 2022 10:16

Syncona's Achilles says cancer treatment shows promise; seals buy

(Alliance News) - Syncona Ltd on Thursday noted a promising safety profile for a cancer therapy concocted by one investee, and separately announced the completion of an acquisition in the retinal gene therapy space.

Read more
29 Nov 2022 09:05

TOP NEWS: AstraZeneca to buy Neogene for cancer treatment

(Alliance News) - AstraZeneca PLC said it agreed to buy Neogene Therapeutics Inc for the treatment of cancer, as also noted by healthcare company Syncona Ltd on Tuesday.

Read more
29 Nov 2022 08:57

LONDON MARKET OPEN: Stocks up as protests in China deterred by police

(Alliance News) - The FSTE 100 opened in the green on Tuesday as investors were reassured that civil unrest in China would be short lived amid unyielding action by the authorities.

Read more
29 Nov 2022 07:50

LONDON BRIEFING: easyJet boasts "record bounce back" as loss narrows

(Alliance News) - Stocks in London were set to open slightly higher on Tuesday as unrest in the world's second largest economy continued.

Read more
17 Nov 2022 10:53

Syncona net assets rise in half year and outlines 10-year growth plans

(Alliance News) - Syncona Ltd on Thursday said net assets increased in the first half of its financial year, as it outlined plans to grow its net assets to GBP5 billion within the next 10 years.

Read more
17 Nov 2022 08:16

Syncona makes 'positive' operational and clinical progress in H1

(Sharecast News) - Healthcare company Syncona said on Thursday that it had delivered "positive operational and clinical progress" across its portfolio against a challenging macro backdrop in the six months ended 30 September.

Read more
15 Nov 2022 14:41

IN BRIEF: Syncona notes investee Freeline's third-quarter loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes third-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline's pretax loss in the third quarter that ended September 30 narrows to USD65.9 million from USD105.7 million a year prior. Research & development expenses decrease to USD53.6 million from USD70.8 million, and total operating expenses fall by 27% to USD78.6 million from USD108.0 million. Freeline continues to make no revenue. Freeline enters a definitive agreement to sell its chemistry, manufacturing & control focused German subsidiary and related intellectual property for USD25 million, with the sale being subject to price adjustments.

Read more
10 Nov 2022 21:19

TRADING UPDATES: Zambeef expects profit jump; Mobile Streams wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
10 Nov 2022 15:52

UK earnings, trading statements calendar - next 7 days

Friday 11 November 
Beazley PLCHalf Year Results
Permanent TSB Group Holdings PLCTrading Statement
TheWorks.co.uk PLCTrading Statement
Urban Logistics REIT PLCHalf Year Results
Monday 14 November 
Atalaya Mining PLCQ3 Results
Biome Technologies PLCTrading Statement
Cake Box Holdings PLCHalf Year Results
Diversified Energy Co PLCTrading Statement
HgCapital Trust PLCQ3 Results
Informa PLCTrading Statement
Kainos Group PLCHalf Year Results
MySale Group PLCFull Year Results
S4 Capital PLCQ3 Results
SRT Marine Systems PLCHalf Year Results
Totally PLCHalf Year Results
Tuesday 15 November 
AdEPT Technology Group PLCHalf Year Results
BAE Systems PLCTrading Statement
Gear4Music PLCHalf Year Results
Imperial Brands PLCFull Year Results
Land Securities Group PLCHalf Year Results
Melrose Industries PLCTrading Statement
Ninety One PLC and LtdHalf Year Results
R&Q Insurance Holdings LtdQ1 Results
Speedy Hire PLCHalf Year Results
Vesuvius PLCTrading Statement
Vodafone Group PLCHalf Year Results
Wincanton PLCHalf Year Results
Workspace Group PLCHalf Year Results
Wednesday 16 November 
Aristocrat Leisure LtdFull Year Results
British Land Co PLCHalf Year Results
Castings PLCHalf Year Results
CMC Markets PLCHalf Year Results
Enteq Technologies PLCHalf Year Results
Experian PLCHalf Year Results
Mediclinic International PLCHalf Year Results
Premier Foods PLCHalf Year Results
Renold PLCHalf Year Results
Sage Group PLCFull Year Results
Schroder Global Real Estate SecuritiesHalf Year Results
Schroder Real Estate Investment Trust LtdHalf Year Results
SSE PLCHalf Year Results
Thursday 17 November 
Burberry Group PLCHalf Year Results
Close Brothers Group PLCTrading Statement
Fuller, Smith & Turner PLCHalf Year Results
Grainger PLCFull Year Results
Great Portland Estates PLCHalf Year Results
Halma PLCHalf Year Results
Integrated Diagnostics Holdings PLCQ3 Results
Intermediate Capital Group PLCHalf Year Results
International Distributions Services PLCHalf Year Results
Investec PLC and LtdHalf Year Results
Keller Group PLCTrading Statement
Mitie Group PLCHalf Year Results
Pershing Square Holdings LtdQ3 Results
Redcentric PLCHalf Year Results
Seraphim Space Investment Trust PLCQ1 Results
Spirax-Sarco Engineering PLCTrading Statement
Syncona LtdHalf Year Results
Tyman PLCTrading Statement
Virgin Money UK PLCFull Year Results
Zytronic PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
3 Nov 2022 11:50

Syncona portfolio firm Autolus Therapeutics widens quarterly loss

(Alliance News) - Syncona Ltd on Thursday noted that its portfolio company Autolus Therapeutics PLC had widened its third quarter loss as it continued to progress its candidate pipeline.

Read more
24 Oct 2022 08:53

Syncona to acquire retinal therapy firm Applied Genetic Technologies

(Alliance News) - Syncona Ltd on Monday it will expand its retinal gene therapy pipeline with the acquisition of a Florida-based biotechnology company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.